Table 5 Clinical outcomes in rosuvastatin trial
Outcomes | Rosuvastatin (N = 18) | Placebo (N = 16) | HR (95% CI) |
|---|---|---|---|
Composite of all-cause mortality or non-fatal myocardial infarction within 30 days after surgery, n (%) | 1 (5.6) | 0 (0.0) | –a |
 All-cause mortality, n (%) | 0 (0.0) | 0 (0.0) |  |
 Non-fatal myocardial infarction, n (%) | 1 (5.6%) | 0 (0.0%) |  |
Myocardial infarction, n (%) | 1 (5.6%) | 0 (0.0%) | –a |
MINS, n (%) | 2 (11.1) | 2 (12.5%) | 0.92 (0.13–6.64) |
Cardiac revascularization, n (%) | 0 (0.0) | 0 (0.0) | –a |
Venous thromboembolism, n (%) | 0 (0.0) | 0 (0.0) | –a |
Postoperative infection, n (%) | 4 (22.2) | 1 (6.3) | 3.36 (0.37–30.4) |
Postoperative sepsis, n (%) | 2 (11.1) | 0 (0.0) | –a |
Congestive heart failure, n (%) | 0 (0.0) | 0 (0.0) | –a |
Re-hospitalization for vascular reason, n (%) | 0 (0.0) | 0 (0.0) | –a |
Statin-induced myopathy, n (%) | 0 (0.0) | 0 (0.0) | –a |